- Hypertrophic Cardiomyopathy (HCM)
- Eyecare
- Urothelial Carcinoma
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Asthma
- Atrial Fibrillation
- COVID-19
- Cardiovascular Diseases
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
'The Immortal Life of Henrietta Lacks' by Rebecca Skloot is a 'Must-Read,' Per Melissa Soliz of Coppersmith Brockelman PLC
Melissa A. Soliz, J.D., of Coppersmith Brockelman PLC is one of 12 winners in this year's Emerging Leaders in Healthcare feature. In an interview with MHE, Soliz recommends the book, “The Immortal Life of Henrietta Lacks” by Rebecca Skloot to those in healthcare because "it is a compelling portrayal of how the law, ethics, ownership and business interests, and health inequities impact patient care and the advancement of that care from a generational perspective."
Melissa A. Soliz, J.D., of Coppersmith Brockelman PLC is one of 12 winners in this year's Emerging Leaders in Healthcare feature. In an interview with MHE, Soliz recommends the book, “The Immortal Life of Henrietta Lacks” by Rebecca Skloot to those in healthcare because "it is a compelling portrayal of how the law, ethics, ownership and business interests, and health inequities impact patient care and the advancement of that care from a generational perspective."
The book is about Henrietta Lacks, a Black mother of five children, who died in her early 30s of cervical cancer. The cells from her tumor were taken without her knowledge to develop the HeLa cell line that has been used in countless scientific research studies. Her story influenced the establishment of the Common Rule for federally funded human subjects research, including requirements for obtaining informed consent.
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
35th World AIDS Day Marks 20 Years of PEPFAR: Challenges and Strategies to Combat HIV/AIDS
November 29th 2023PEPFAR, having invested $100 billion and saved 25 million lives in the global fight against HIV/AIDS, faces Congressional hurdles in its reauthorization due to abortion debates. Despite widespread support and no evidence of abortion-related activities, the legislative process is at a standstill. Members of PEPFAR and authors of a recent editorial stress the significance of PEPFAR and advocate for integrating behavioral and social science into healthcare programs to achieve UNAIDS targets and address barriers in HIV/AIDS testing and treatment.
Read More
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen
Study Raises Concerns Over Insurance Barriers to HIV Prevention Medications
November 29th 2023Despite its efficacy, PrEP remains underutilized compared to the need for it. High costs are among the barriers to PrEP use, along with limited knowledge among clinicians, lack of health insurance, stigma, and underestimation of personal HIV risk.
Read More
